Although genetic testing includes t...

Although genetic testing includes the analysis of DNA, RNA, chromosome proteins, and certain metabolites, it is DNA- and RNA-based molecular genetic testing that has catapulted into mainstream medicine during the past decade. (12) Molecular genetic testing is now available in succession a clinical basis for more than 750 inherited conditions.3 There are three representations of these heritable disorders: (1) single-gene disorders caused by means of a mutation in one gene that is inherited in a Mendelian fashion (i.e., autosomal dominant, autosomal recessive, X-linked); (2) contiguous gene disorders caused by means of deletion or duplication of multiple adjacent gene that are inherited in a Mendelian fashion (eg 22q112 deletion, which is almost as general as Down syndrome); and (3) mitochondrial disorders caused from mutation or deletion of mitochondrial DNA that is inherited maternally (eg Kearns-Sayre syndrome) The prevalence of the greatest in quantity common of these heritable disorders is undivided per 1,000 persons, but in the greatest degree are considerably rarer. The customary complex disorders that comprise the "bread and butter" of primary care, similar as breast cancer, hypertension, asthma, and crack lip, are attributed to the interaction of diplomatic variations in multiple genes and environmental factors, and they are not to this time amenable to molecular genetic testing. Thus, existing molecular genetic touchstones are not useful as population-based screening ordeals to stratify patient risks for the project of introducing risk-reducing medications or lifestyle changes.

Molecular genetic testing for heritable disorders is used for the following purposes: (1) diagnosis, in which testing confirms or debars a known or suspected genetic disorder in a symptomatic patient; (2) confirmation of a diagnosis, in which testing establishes a diagnosis suspected in a patient who does not encounter diagnostic criteria; (3) predictive testing, which is proffered to asymptomatic persons who, based onward their family history, are at risk for developing a disorder; (4) carrier testing, which identifies human frames with a genetic mutation for a disorder inherited in an autosomal recessive or X-linked recessive manner; and (5) prenatal diagnosis, in which testing determines whether a fetus is affected with a particular disorder.

In predictive testing, carrier testing, and prenatal diagnosis, it is essential that single affected family member be exhibitioned before testing at-risk relatives. Testing of an affected relative is required for united of two reasons. First, it can confirm the diagnosis. For example, the molecular genetic testing for Huntington's disease (HD) involves assessing the size of the CAG trinucleotide repeat in the HD gene a standard that can be performed and interpreted accurately for any symptomatic someone However, mutations in other gene so as HDL2, can mimic HD Thus, if an affected someone with an unconfirmed clinical diagnosis of HD actually has a mutation in HDL2 testing at-risk asymptomatic relatives for mutations in the HD gene will yield falsely reassuring normal flows Conversely, testing for mutations in HDL2 will yield the accurate information (i.e., the disorder for which relatives are at increased risk). secondary testing the affected family member is important to discover the family-specific mutation. For example, more than 825 mutations causing familial adenomatous polyposis have been identified in the APC gene Each mutation "run true" in a family (i.e., kindred relatives are at increased risk no other than for the mutation known to be in the family). Before predictive testing can be put forwarded to an at-risk family member, the cancer-causing mutation specific to that family must be identified to assure accurate interpretation of "negative" experiment results.

Genetic testing differs from traditional medical testing in brace ways. First, genetic test be the effects always have implications for disease risk for the patient's family as well as the patient. inferior genetic testing may be used for the individual purpose of personal decision making rather than medical care. For example, pair people who are carriers for cystic fibrosis might elect to have prenatal diagnosis and terminate an affected fetus, have preimplantation genetic diagnosis, adopt, or decide not to have children. Asymptomatic at-risk parts whose predictive testing identifies a 100 percent risk for HD may choice to shorten their formal education or select different investment options.

Genetic counseling is as essential to care of the patient with a genetic disorder as the testing itself. Genetic counseling involves determining the advantages and disadvantages of testing and the potential implications of the standard results for both the patient and the patient's family; education about the nature and cause of the inherited disorder; information to further informed medical and personal decision making; and psychosocial support and referral. Although genetic counseling can be provided on any health care provider with the appropriate experience and training, family physicians may fix upon to refer patients to a genetics professional because of the time necessityed to become familiar with the relevant aspects of the disorder, testing, management, and disease-specific psychosocial support services. Other factors include the time be in want ofed to identify at-risk relatives and to fit with the patient and interested family members to discuss the issues mostly important to them and poor reimbursement according to third-party payers. (4)